Management practice of hematologic toxicities and its determinants among breast cancer patients treated with doxorubicin-cyclophosphamide followed by paclitaxel regimen in cancer centers, Northwest Ethiopia, 2022
JavaScript is disabled for your browser. Some features of this site may not work without it.
Management practice of hematologic toxicities and its determinants among breast cancer patients treated with doxorubicin-cyclophosphamide followed by paclitaxel regimen in cancer centers, Northwest Ethiopia, 2022